Online inquiry

IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15313MR)

This product GTTS-WQ15313MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Allergic asthma, Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15313MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3361MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ5029MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ2523MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 334
GTTS-WQ8709MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ446MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ4150MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BI-754091
GTTS-WQ684MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ6033MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CNTO 1275
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW